BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37265085)

  • 1. Outcomes and cost-effectiveness comparisons of progestin-primed ovarian stimulation, GnRH antagonist protocol, and luteal phase stimulation for fertility preservation.
    Zhao W; Sun P; Li T; Li Y; Liang X; Li J
    Int J Gynaecol Obstet; 2023 Nov; 163(2):645-650. PubMed ID: 37265085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations.
    Zhou R; Dong M; Huang L; Wang S; Fan L; Liang X; Zhang X; Liu F
    Front Endocrinol (Lausanne); 2023; 14():1117513. PubMed ID: 37143731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of random-start progestin-primed ovarian stimulation for fertility preservation.
    Huang H; Itaya Y; Samejima K; Ichinose S; Narita T; Matsunaga S; Saitoh M; Takai Y
    J Ovarian Res; 2022 Jan; 15(1):2. PubMed ID: 34983605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols.
    Mathieu d'Argent E; Ferrier C; Zacharopoulou C; Ahdad-Yata N; Boudy AS; Cantalloube A; Levy R; Antoine JM; Daraï E; Bendifallah S
    J Ovarian Res; 2020 Feb; 13(1):18. PubMed ID: 32054493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-inferiority of progestin-primed ovarian stimulation versus GnRH antagonist protocol: A propensity score-weighted analysis.
    Duc Thang L; Bao Long H; Thi Thu Trang D; Ngoc Quy P; Thi Mai Phuong G; Thi Hanh B; Trong Thach T; Thi Lien Huong N; Hoang L; Hugues JN
    J Formos Med Assoc; 2024 Apr; 123(4):523-529. PubMed ID: 38092654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the cumulative live birth rates after 1 in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: a propensity score-matched study.
    Chen H; Teng XM; Sun ZL; Yao D; Wang Z; Chen ZQ
    Fertil Steril; 2022 Oct; 118(4):701-712. PubMed ID: 35940929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis.
    Du M; Zhang J; Li Z; Liu X; Li J; Liu W; Guan Y
    Front Endocrinol (Lausanne); 2021; 12():705264. PubMed ID: 34589055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed Gonadotropin-Releasing Hormone Antagonist Protocol
    Dong M; Sun L; Huang L; Wang F; Zhang X; Liu F
    Front Endocrinol (Lausanne); 2021; 12():690575. PubMed ID: 34867773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oocyte competence is comparable between progestin primed ovarian stimulation with Norethisterone acetate (NETA-PPOS) and GnRH-antagonist protocols: A matched case-control study in PGT-A cycles.
    Vaiarelli A; Cimadomo D; Ruffa A; Rania E; Pittana E; Gallo C; Fiorenza A; Alviggi E; Alfano S; Carmelo R; Trabucco E; Alviggi C; Rosaria Campitiello M; Rienzi L; Maria Ubaldi F; Venturella R
    Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():4-10. PubMed ID: 38171151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medroxyprogesterone acetate: an alternative to GnRH-antagonist in oocyte vitrification for social fertility preservation and preimplantation genetic testing for aneuploidy.
    Giles J; Cruz M; Cobo A; Vidal C; Requena A; Remohi J; Bosch E
    Reprod Biomed Online; 2023 Aug; 47(2):103222. PubMed ID: 37290978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestin-primed ovarian stimulation versus GnRH antagonist protocol in poor responders: Risk of premature LH surge and outcome of oocyte retrieval.
    Kao TC; Hsieh YC; Yang IJ; Wu MY; Chen MJ; Yang JH; Chen SU
    J Formos Med Assoc; 2023 Jan; 122(1):29-35. PubMed ID: 36123235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of a GnRH Agonist Trigger Following a GnRH Antagonist or Flexible Progestin-Primed Ovarian Stimulation Cycle.
    Kalafat E; Turkgeldi E; Yıldız S; Dizdar M; Keles I; Ata B
    Front Endocrinol (Lausanne); 2022; 13():837880. PubMed ID: 35663329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH antagonist protocol versus progestin-primed ovarian stimulation in patients with polycystic ovary syndrome: a systematic review and meta-analysis.
    Deng R; Wang J; He J; Lei X; Zi D; Nong W; Lei X
    Arch Gynecol Obstet; 2024 Apr; 309(4):1151-1163. PubMed ID: 37957365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative live birth rate of in vitro fertilization cycle via progestin-primed ovarian stimulation versus gonadotropin-releasing hormone antagonist protocol in infertile women with normal ovarian reserve: an open-label, randomized controlled trial.
    Ye H; Shi L; Quan X; Hou M; Ma H; Xue S; Yu Z; Chen Q; Sun L
    Hum Fertil (Camb); 2024 Dec; 27(1):2316005. PubMed ID: 38357937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of euploidy rates of blastocysts in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation.
    La Marca A; Capuzzo M; Sacchi S; Imbrogno MG; Spinella F; Varricchio MT; Minasi MG; Greco P; Fiorentino F; Greco E
    Hum Reprod; 2020 Jun; 35(6):1325-1331. PubMed ID: 32395749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study.
    Huang P; Tang M; Qin A
    J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):99-102. PubMed ID: 30321608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestin Primed Ovarian Stimulation (PPOS) protocol yields lower euploidy rate in older patients undergoing IVF.
    Pai AH; Sung YJ; Li CJ; Lin CY; Chang CL
    Reprod Biol Endocrinol; 2023 Aug; 21(1):72. PubMed ID: 37550681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the neonatal outcomes of progestin-primed ovarian stimulation and flexible GnRH antagonist protocols: a propensity score-matched cohort study.
    Du M; Zhang J; Ren B; Guan Y
    Front Endocrinol (Lausanne); 2023; 14():1156620. PubMed ID: 37396165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve.
    Turkgeldi E; Yildiz S; Cekic SG; Shakerian B; Keles I; Ata B
    Hum Fertil (Camb); 2022 Apr; 25(2):306-312. PubMed ID: 32672129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.